Consino and Pfizer have signed a four-valent meningococcal combination vaccine promotion agreement.

Read: Invasive meningococcal meningitis is a serious infectious disease caused by neser bacteria.!---- / On July 25, Considine BioAG and Pfizer Investment Co., Ltd. signed a promotional service agreement in Shanghai.The tetravalent meningococcal combination vaccine developed by Consino Bio will be the head of Pfizer's academic promotion in the Chinese mainland market after it has been approved by the State Drug Administration (NMPA).'s cooperation marks an important milestone for the two companies to work together to meet the unmet medical needs of the Chinese people.invasive meningococcal meningitis (hereinafter referred to as the brain) is a serious infectious disease caused by neseritis of meningitis, in China, children under 5 years of age, especially children between 6 months and 2 years of age, the highest incidence, if not treated in a timely manner, the mortality rate can be as high as 50%.vaccination is an effective measure to prevent invasive meningitis. MenhyciaTM, a four-valent meningococcal conjugate vaccine developed byConcino Bio, is one of the core products of Concino Bio's 16 innovative vaccines.used to prevent invasive meningococcal meningitis meningococcal meningitis, it combines four common pathogenic meningococcal serogroups of A, C, W135 and Y, in combination with carrier protein CRM197, and has a wider protection compared to the meningococcal vaccine currently used in China for children under 2 years of age.December 2019, China's State Drug Administration has added® MenhyciaTM to the list of priority-reviewed varieties, becoming the first tetravalent meningococcal combination vaccine to be added to the list. "The partnership between Consino Bio and Pfizer opened the first innovation model led by an innovative Chinese vaccine company, with multinationals promoting the innovation model," said Yu Xuefeng, Chairman and CEO ofConsino BioAG.we are pleased to partner with Pfizer to provide the Chinese people with an innovative meningococcal vaccine made in China. "This partnership reflects Pfizer's commitment to actively supporting China's health care reform," said Mr. Wu Wei, Chief Operating Officer, Pfizer Biopharmaceutical group china,.highlights Pfizer's efforts to increase vaccine accessibility, reduce the threat of infectious diseases and meet the health needs of the Chinese people."